MAIA Biotechnology, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
MAIA Biotechnology, Inc. (MAIA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.37 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-10
- MAIA Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.49, a 19.46% decline year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.85, a 30.28% increase year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.42, a 65.20% decline year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $4.08.
- MAIA Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.73, a 28.22% decline from fiscal 2024.
- MAIA Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.41, a 5.49% decline from fiscal 2023.
- MAIA Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.55, a 46.54% decline from fiscal 2022.
- MAIA Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.77.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.37 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $1.49 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $1.73 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $1.81 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $1.80 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $1.85 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $2.41 10-K · filed 2025-03-21 | |||
| 2024-09-30 | $2.43 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $2.41 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $1.42 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $2.55 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $3.12 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $3.26 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $4.08 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $4.77 10-K · filed 2023-03-24 | |||
| 2022-09-30 | $4.84 10-Q/A · filed 2023-02-06 | |||
| 2022-06-30 | $9.00 10-Q · filed 2022-08-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |